SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard), today announced that it has received Orphan Drug designation from the European Commission for AX200 in the treatment of Spinal Cord Injury (SCI). This follows the positive recommendation that SYGNIS received from the EMEA in September.
Orphan Drug designation can be granted for a product that is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the European Union. Read more here
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.